Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults
A Phase 1 Randomized, Open-label, Parallel-group, Active- And Placebo-controlled Study To Assess Safety And Tolerability Of 60, 120, And 200 Mcg Meningococcal Group B Rlp2086 Vaccine In Healthy Adult Subjects
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Florida
-
South Miami、Florida、アメリカ、33143
- Miami Research Associates, Inc.
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
A subject must meet the following inclusion criteria at screening (visit 1) and at randomization (visit 2) to be considered for enrollment in the study:
- Male or female subjects between the ages of 18 and 40.
- Healthy male or female subjects as determined by medical history, physical examination, and judgment of the investigator.
- Male or female subject who is considered biologically capable of having children must agree to commit to the use of a reliable method of birth control for the duration of the study and for 30 days after early discontinuation. A subject is still biologically capable of having children, even if he or she is using contraceptives or if his or her sexual partner is sterile or using contraceptives.
In addition a subject must meet the following inclusion criteria at randomization (visit 2) to be considered for enrollment in the study. The referred blood and urinalysis tests (inclusion criterion 5) will be performed on a blood and urine sample taken at visit 1:
- Female subjects of childbearing potential with a negative urine pregnancy test prior to study drug administration. Note: this criterion will apply to each vaccination visit and to the last study visit.
- Laboratory blood and urinalysis tests results within the per-protocol normal ranges.
- Able to be contacted by telephone during the study period. Note: this criterion will apply to each study visit.
Exclusion Criteria:
None
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:1
rLP2086 vaccine 60 mcg
|
intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
|
|
実験的:2
rLP2086 vaccine 120 mcg
|
intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
|
|
実験的:3
rLP2086 vaccine 200 mcg
|
intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
|
|
アクティブコンパレータ:4
Tdap vaccine - normal saline - normal saline
|
intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Percentage of Participants With at Least One Adverse Event (AE)
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Alanine Aminotransferase [ALT])
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Aspartate Aminotransferase [AST])
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Total Protein)
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Albumin)
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Alkaline Phosphatase [ALP])
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Total Bilirubin)
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Creatine Phosphokinase [CPK])
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Prothrombin Time [PT])
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Partial Thromboplastin Time [PTT])
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Fibrinogen)
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Hemoglobin)
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (White Blood Cell [WBC])
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Lymphocytes)
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Neutrophils)
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Eosinophils)
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Platelet Count)
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Sodium).
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Potassium).
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Blood Urea Nitrogen [BUN]).
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Serum Creatinine).
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Urine Red Blood Cells [RBC]).
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Urine Protein).
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
|
Percentage of Participants With Change in Severity From Baseline in Laboratory Evaluations (Urine Glucose).
時間枠:Baseline up to Month 7
|
Baseline up to Month 7
|
二次結果の測定
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Meningococcal Immunoglobulin G (IgG) Geometric Mean Titers (GMT)
時間枠:Before Dose 1, 1 month after Dose 2, before Dose 3, 1 month after Dose 3
|
Before Dose 1, 1 month after Dose 2, before Dose 3, 1 month after Dose 3
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Beeslaar J, Mather S, Absalon J, Eiden JJ, York LJ, Crowther G, Maansson R, Maguire JD, Peyrani P, Perez JL. Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older. Vaccine. 2022 Mar 15;40(12):1872-1878. doi: 10.1016/j.vaccine.2022.01.046. Epub 2022 Feb 11.
- Sheldon EA, Schwartz H, Jiang Q, Giardina PC, Perez JL. A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. Hum Vaccin Immunother. 2012 Jul;8(7):888-95. doi: 10.4161/hv.19983. Epub 2012 Jul 1.
研究記録日
主要日程の研究
研究開始
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
最初の投稿
学習記録の更新
投稿された最後の更新 (見積もり)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 6108A1-1004
- B1971004 (その他の識別子:Alias Study Number)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。